Black Diamond Therapeutics, Inc.
BDTX
$1.71
$0.010.59%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 7.31% | 12.00% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 9.72% | -6.52% | |||
| Operating Income | -9.72% | 6.52% | |||
| Income Before Tax | 40.22% | -77.88% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 40.22% | -77.88% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 40.22% | -77.88% | |||
| EBIT | -9.72% | 6.52% | |||
| EBITDA | -10.16% | 6.39% | |||
| EPS Basic | 40.37% | -77.36% | |||
| Normalized Basic EPS | -13.84% | 7.07% | |||
| EPS Diluted | 39.58% | -76.53% | |||
| Normalized Diluted EPS | -13.84% | 7.07% | |||
| Average Basic Shares Outstanding | 0.25% | 0.28% | |||
| Average Diluted Shares Outstanding | 0.25% | 0.28% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||